These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27751627)

  • 1. A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.
    Ramakrishnan B; Viswanathan K; Tharakaraman K; Dančík V; Raman R; Babcock GJ; Shriver Z; Sasisekharan R
    Trends Microbiol; 2016 Dec; 24(12):933-943. PubMed ID: 27751627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological considerations for developing antibody therapeutics for Influenza A.
    Chan-Hui PY; Swiderek KM
    Hum Vaccin Immunother; 2016; 12(2):474-7. PubMed ID: 26325257
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Sutton TC; Lamirande EW; Bock KW; Moore IN; Koudstaal W; Rehman M; Weverling GJ; Goudsmit J; Subbarao K
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29046448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Neutralizing Antibodies for HIV Eradication.
    Stephenson KE; Barouch DH
    Curr HIV/AIDS Rep; 2016 Feb; 13(1):31-7. PubMed ID: 26841901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies.
    Ekiert DC; Wilson IA
    Curr Opin Virol; 2012 Apr; 2(2):134-41. PubMed ID: 22482710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
    Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
    Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
    J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.
    He W; Tan GS; Mullarkey CE; Lee AJ; Lam MM; Krammer F; Henry C; Wilson PC; Ashkar AA; Palese P; Miller MS
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11931-11936. PubMed ID: 27698132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis.
    Clementi N; Criscuolo E; Castelli M; Clementi M
    New Microbiol; 2012 Oct; 35(4):399-406. PubMed ID: 23109007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling influenza with broadly neutralizing antibodies.
    Corti D; Cameroni E; Guarino B; Kallewaard NL; Zhu Q; Lanzavecchia A
    Curr Opin Virol; 2017 Jun; 24():60-69. PubMed ID: 28527859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Anti-Influenza Virus Antibody Inhibits Viral Infection by Reducing Nucleus Entry of Influenza Nucleoprotein.
    Yoon A; Yi KS; Chang SY; Kim SH; Song M; Choi JA; Bourgeois M; Hossain MJ; Chen LM; Donis RO; Kim H; Lee Y; Hwang DB; Min JY; Chang SJ; Chung J
    PLoS One; 2015; 10(10):e0141312. PubMed ID: 26512723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
    Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
    J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epitope analysis of the hemagglutinin molecule of the Victoria lineage influenza B viruses].
    Sorokin EV; Tsareva TR; Sominina AA; Pisareva MM; Komissarov AV; Kosheleva AA; Grudinin MP
    Vopr Virusol; 2014; 59(6):27-31. PubMed ID: 25929033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Epitopes for Neutralizing Antibodies Against H10N8 Avian Influenza Virus Hemagglutinin.
    Hu JF; Sun CY; Rao MD; Xie LZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Aug; 38(4):404-10. PubMed ID: 27594152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.
    Shen C; Chen J; Li R; Zhang M; Wang G; Stegalkina S; Zhang L; Chen J; Cao J; Bi X; Anderson SF; Alefantis T; Zhang M; Cai X; Yang K; Zheng Q; Fang M; Yu H; Luo W; Zheng Z; Yuan Q; Zhang J; Wai-Kuo Shih J; Kleanthous H; Chen H; Chen Y; Xia N
    Sci Transl Med; 2017 Oct; 9(412):. PubMed ID: 29046433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
    He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
    J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive immunization with influenza haemagglutinin specific monoclonal antibodies.
    Rudraraju R; Subbarao K
    Hum Vaccin Immunother; 2018; 14(11):2728-2736. PubMed ID: 29985756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.